Pharma Jonpi . / 1.1 / .

27 diciembre 2022

Hetero’s COVID-19 ORAL Drug Gets WHO Pre-Qualification . WHO Made a Strong Recommendation For Nirmatrelvir and Ritonavir For Mild And Moderate COIVID19 Patients At Highest Risk of Hospital Admission .

 



Pharma Jonpi en 12:32
‹
›
Inicio
Ver versión web

En tres lineas ...

  • Pharma Jonpi
  • pharma jonpi
Con la tecnología de Blogger.